Compare AbCellera Biologics Inc (ABCL) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Synopsys, Inc. — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while Synopsys, Inc. trades at $430.07 (market cap $83.61B). The key difference: Synopsys, Inc. is far larger — about 35.6× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Synopsys, Inc. nearer its low. Which is the better fit depends on your goals.
| ABCL | SNPS | |
|---|---|---|
Market Cap | $2.35B | $83.61B |
Sector | Health | Technology |
52-Week High | $8.12 | $645.59 |
52-Week Low | $2.78 | $380.47 |
Enterprise Value | $1.99B | $91.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Synopsys (SNPS) trades at $436.63, down 0.12% on the day, with a bearish technical signal despite strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $3.35 exceeding expectations, and maintains robust gross margins of 73.47%. Recent news highlights the company's strategic pivot toward AI-driven design tools, though cash flow trends show volatility with a net outflow of $1.01B in 2025.
Outlook remains positive with a consensus price target of $558.33 implying 28% upside, driven by AI adoption and market positioning. Key risks include high valuation multiples (P/E of 101.21) and execution challenges in shifting business focus. Investors should weigh growth potential against premium pricing and competitive pressures in the semiconductor software space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
